Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 ip once daily for 1

ip once daily for 1 month) inhibits the growth of Apc mutation-driven tumors

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors

1158/0008-5472

including a full program of reproductive toxicity studies

3'-biindol]-2-one

Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 ip once daily for 1Azilsartan medoxomil also known as TAK 491, is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. Azilsartan medoxomil is a useful and attractive new option for lowering BP in patients with essential hypertension, particularly for those not able to tolerate other antihypertensive drugs. Further studies are required to evaluate the effects of azilsartan medoxomil on